Objective To evaluate the clinical curative effect of immune adjuvant treatment in treating children recurrent respiratory tract infections by meta analysis method.  Methods  EMBASE (1974.9-2013.9), PUBMED (1966~2013), the Cochrane Register of Controlled Trials (2013.1) and VIP (1989.9-2013.9), WanFang Data (1994.1-2013.9), CNKI (1979.1-2013.9) were retrived by using computer. And domestic published information on papers and conference in recent 1 year was manually retrived. Literature were selected according the inclusion and exclusion criteria. Information and evaluation into the study of methodological quality was extracted using the Cochrane Revman5.3 software for Meta analysis. Results Participants included 13 researches, 1088 cases of pediatric patients. Meta analysis showed that immune adjuvant combined with conventional treatment group can improve the patient's immune adjuvant T-lymphocyte subsets CD3 (WMD = 7.97, 95%CI = 5.6, 10.34, P = 0.000), CD4 (WMD = 5.44, 95%CI=1.27, 9.6, P = 0.010) and improve the immunoglobulin IgA (WMD = 0.43, 95%CI = 0.08, 0.77, P = 0.010),IgG (WMD = 1.07, 95%CI = 0.25, 1.89, P =0.010), and can delay the onset of several days of RRI (WMD = -5.14, 95%CI : 6.72, 3.56, P = 0.040). The CD8 (WMD = 0.7, 95%CI : 0.19, 1.59, P = 0.130) and CD4/CD8 (WMD = 0.25, 95%CI : 0.04, 0.45, P = 0.130), IgM (WMD = 0.04, 95%CI : -0.05, 0.12, P = 0.370) and the incidence of adverse reactions (WMD = 1.5, 95%CI : 0.52, 4.28, P = 0.450) had no statistically significant difference between experimental group and control group. Conclusions The results of Meta-analysis indicate that immune adjuvant combined with conventional treatment can reduce the frequency of recurrent respiratory infection with safety. Howerver, due to the number and quality of included studies, more large-scale and high-quality RCTs are needed.